Relugolix and radiation therapy may be a safe, effective combination for treating prostate cancer

Mar 13 2024University Hospitals Cleveland Medical Center This work is published in JAMA Oncology.

Remarkably, Relugolix demonstrated a faster return to baseline testosterone levels compared to traditional therapies, a crucial aspect for patients' quality of life post-treatment. This rapid recovery could significantly reduce the adverse impacts associated with long-term testosterone suppression, such as cardiovascular risks and bone density reduction."

For the first time, Dr. Spratt and colleagues demonstrated that there was no difference between leuprolide, an LHRH agonist, and relugolix in time to castration resistant-prostate cancer, a near uniformly lethal form of the disease.

Education Education Latest News, Education Education Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novel oral hormone therapy shows promising results for prostate cancer treatment with radiation therapyA study led by Daniel Spratt, M.D., Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer. This work is published in JAMA Oncology.
Source: medical_xpress - 🏆 101. / 51 Read more »